CHICAGO — Nearly three-quarters of older adults with advanced cancer value quality of life over extending survival, according to study results presented at ASCO Annual Meeting.However, data showed that regardless of patient preference for quality of life or survival, clinical outcomes appeared to be similar.| www.healio.com
A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia and an NPM1 m...| ascopost.com
Joshua Zeidner, MD, and colleagues report that a combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia showed high rates of complete remission in an early-phase clinical trial.| UNC Lineberger